Track market-moving stories before they get noisy

Agreement will add iconic supplement brands to cbdMD's growing multi-brand consumer wellness platform, anticipated to increase revenues to approximately $30 million.

, /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), a leading consumer wellness company, today announced that it has entered into a definitive asset purchase agreement to acquire operating assets and brands of Twinlab, including Twinlab, Reserveage, Metabolife, and Alvita Tea. The acquisition is being conducted through an assignment for the benefit of creditors (ABC) proceeding and is subject to court approval and customary closing conditions.

The transaction is expected to give the acquired brands a stable home and provide an orderly path forward for the business's legacy obligations, allowing the brands, their products, and their customer relationships to continue uninterrupted. For customers, retailers, and distribution partners, it means the products they rely on will remain available and are backed by a company committed to investing in them for the long term.

This transaction is expected to reduce cbdMD's revenue concentration in the hemp category and mitigate risks associated with the evolving regulatory environment for hemp-derived products. Based on unaudited financial information, the combined unaudited trailing twelve months of revenue ending June 2026 totals approximately $30 million, which would represent an increase of approximately 40% relative to cbdMD's standalone revenue for the same period. The incremental revenue is expected to generate positive contribution after transaction and integration costs. This combined revenue figure is provided for illustrative purposes only and should not be viewed as indicative of future results.

The transaction marks a significant step in cbdMD's evolution into a broader multi-brand consumer wellness platform spanning supplements, sports nutrition, longevity, functional wellness, pet wellness, hemp-derived products, and adjacent consumer health categories. As the platform grows beyond its origins in CBD and hemp, the Company expects its identity to evolve to reflect the full breadth of consumer wellness it now serves.

Founded in 1968, Twinlab is one of the most recognized names in legacy supplements and sports nutrition, bringing decades of consumer recognition, category credibility, retail relevance in serving 50,000 retail outlets, including Vitamin Shop and GNC in addition to a strong Amazon presence, and product heritage across vitamins, minerals, active lifestyle, beauty and performance nutrition.

"Twinlab is the kind of brand equity that companies spend decades trying to build," said Ronan Kennedy, CEO of cbdMD. "The brands, distribution channels, and team are highly complementary to what we already operate, and this transaction gives these brands the stability and support they need for their next chapter. We believe there is a significant opportunity to build on cbdMD's revenue growth by applying our marketing, creative, and ecommerce resources to drive brand awareness and expand direct-to-consumer sales, alongside the strong wholesale and retail presence these brands already have. From the fundamentals of nutrition to the frontier of modern wellness, the combined portfolio is a unique offering in consumer wellness."

"cbdMD is the right home for these brands," said Anthony Zolezzi, Chief Executive Officer of Twinlab. "Together, we will bring a uniquely complete wellness portfolio spanning foundational vitamins, minerals, and nutrition through botanicals, beauty, longevity, functional mushrooms, cannabinoids, and the emerging breakthroughs defining where this industry is headed. We believe no other company can serve consumers across more needs, more moments, and more stages of life than we now can together. This combination will pair decades of heritage and category credibility with a modern, marketing-driven platform and the resources to reintroduce these products to a new generation of consumers. It positions the brands, and the people behind them, for a strong future." 

Upon closing of the acquisition the acquired portfolio will expand cbdMD's reach into additional consumer need states, including daily wellness, active lifestyle, weight management, longevity, recovery, beauty and functional supplementation. Reserveage brings premium longevity, resveratrol, collagen, and beauty-from-within positioning; Metabolife will bring established weight management brand recognition products.

The agreement follows cbdMD's earlier acquisition and integration of Bluebird Botanicals and reflects the Company's continued strategy of building a portfolio of trusted wellness brands that benefit from shared infrastructure, operational alignment, product innovation, and modern commerce execution.

In connection with entering into the agreement, cbdMD has filed a Current Report on Form 8-K with the Securities and Exchange Commission, which includes additional details regarding the transaction and conditions for closing.

About cbdMD, Inc.
cbdMD, Inc. is a consumer wellness company focused on building a multi-brand platform across CBD, hemp-derived wellness, pet wellness, botanical wellness, supplements, longevity, functional wellness, and related consumer health categories. The Company's portfolio includes cbdMD, Paw CBD, Oasis, Bluebird Botanicals. The Company is focused on quality, transparency, compliance, consumer trust, product innovation, ecommerce, wholesale, retail support, and the development of a broader wellness platform serving multiple consumer needs. For more information, visit www.cbdmd.com.

About Twinlab

Founded in 1968, Twinlab is a heritage leader in nutritional supplements and sports nutrition, with a decades-long reputation for quality and innovation across vitamins, minerals, amino acids, and performance nutrition. The Twinlab family of brands includes Reserveage, a premium longevity and beauty-from-within brand known for its resveratrol, collagen, and healthy-aging products; Metabolife, a recognized name in weight management and Rip Fuel for performance Sports. Together, these brands have built lasting consumer trust and broad distribution across retail, wholesale, and ecommerce channels.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, statements regarding the proposed acquisition, expected revenues, revenue increases, the ability to obtain court approval and complete the transaction, integration plans, brand portfolio development, product availability, and ecommerce. These statements are based on management's current expectations, estimates, and projections and are subject to significant risks and uncertainties that could cause actual results to differ materially from those anticipated. Such risks include, but are not limited to, court approval of the ABC and complete the transaction on the anticipated terms or timeline, satisfy closing conditions, successfully integrate acquired assets and brands, retain key employees and business relationships, maintain wholesale and retail relationships, execute ecommerce and marketplace strategies, develop new product categories, achieve anticipated operational efficiencies and cost savings, manage costs and capital requirements, maintain regulatory compliance across all product categories, access capital on favorable terms, the risk that the unaudited financial information regarding the acquired brands is inaccurate or that audited financial statements meeting the requirements of Regulation S-X cannot be timely obtained, and other risks described in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Contacts

Investors:
cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer
[email protected]
(704) 445-3064

SOURCE cbdMD, Inc.

Accelerating Oasis Beverage Momentum, a Full Quarter of Bluebird Botanical Contribution, and Advancing Federal Hemp Legislation Strengthen the Company's Positioning for Competing under Pending Federal Regulations

, /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading and most trusted CBD companies and operator of the cbdMD, Bluebird Botanicals, and Paw CBD brands, along with its hemp-derived THC beverage brand Oasis and functional-mushroom brand ATRx Labs, today announced financial results for the third quarter of fiscal year 2026, ended June 30, 2026.

The Company delivered 20% year-over-year revenue growth, driven by a 61% increase in wholesale net sales, increased distribution of its Oasis beverage brand, and the first full quarter of contribution from the recently acquired Bluebird Botanicals.

"The third quarter was another quarter of top-line growth and real strategic progress," said Ronan Kennedy, Chief Executive Officer and Chief Financial Officer of cbdMD. "Revenue was up 20% year-over-year, our Oasis beverage brand sales continued to grow, and Bluebird Botanicals contributed a full quarter of revenue for the first time. We were not satisfied with our bottom line this quarter but the shortfall was largely the result of deliberate choices. We absorbed one-time costs tied to M&A due diligence and other one-time legal costs, continued to invest in product development, and did the work required to resolve supply-chain and address state-level compliance issues. During July we implemented cost reduction initiatives that we expect to result in saving potential up to $150,000 per month, as we are running the business to be leaner, more flexible, and well positioned to succeed in the market following the effectiveness of pending federal regulation."

"The regulatory picture is also moving in a more constructive direction," Kennedy continued. "A Senate-driven extension has given cbdMD and the broader industry additional time ahead of the November effective date of the H.R. 5371 Sec. 781 legislation to ensure company compliance with the pending laws, and the number of bipartisan legislative proposals continues to grow, including the Beverage Regulatory Parity Act introduced this week, which would regulate hemp-derived beverages much like alcohol. We believe momentum is building toward a workable federal framework, and that well-capitalized, compliance-focused operators with proven quality, safety data, and clinical credibility, such as cbdMD, will be the ones that benefit as clarity emerges."

Highlights for the Third Quarter of Fiscal 2026 and Notable Business Updates

Revenue growth accelerated year-over-year. Net sales increased 20% to $5.6 million in the third quarter of fiscal 2026 from $4.6 million in the prior-year quarter, with wholesale net sales up 61% year-over-year. For the first nine months of fiscal 2026, net sales rose 12% to $16.2 million from $14.5 million in the prior-year period.
Oasis momentum continued to build. The Company added distribution for Oasis in South Carolina and transitioned to a new distribution partner in Texas that more than quadrupled the number of stores with access to the brand, with continued market growth into the fourth quarter. The recently launched Oasis Mixer has been well received and is contributing to brand growth.  Distributor depletions grew 25% in the third fiscal quarter.  We had record distributor depletions in July up over 34% from the Q3 average and currently at a pace to double in August
Oasis ingredient expansion.  As of today, the Company is introducing a zero-proof Kava beverage under its Oasis brand as a follow-on to the successful Oasis Mixer.  Kava is a natural euphoric people can feel! Immediate, functional, and free of intoxication and regulatory overhang of THC. This is the first of other natural compounds we anticipate launching before the end of the calendar year.
Bluebird Botanicals delivered its first full quarter of revenue. Bluebird Botanicals ("Bluebird") contributed more than $0.5 million revenue in the third quarter of fiscal 2026. After creating an earnings drag during integration in the initial quarter, we expect Bluebird to contribute to both revenue and earnings in the fourth fiscal quarter.
A federal extension creates procedural time to advance a permanent fix on Section 781. While the additional time helps cbdMD and the broader industry manage near-term compliance, its more important benefit is the procedural runway it creates for Congress to put a durable, industry-wide framework in place. A Senate stopgap appropriations proposal released in early August 2026 would, through December 11, 2026, temporarily exempt naturally occurring cannabinoids from the revised total-THC definition and the 0.4 milligram per-container limit under Section 781 of H.R. 5371, signed into law in November 2025, providing additional time ahead of the November 12, 2026 effective date both to bring products into compliance and, more significantly, to advance a permanent legislative solution for the industry. The continuing resolution, H.R. 6500, now moves to the House of Representatives for a vote by the end of September.
Bipartisan legislative momentum is growing. A growing number of bipartisan bills would repeal, delay, modify, or replace Section 781's restrictions, including the White House-supported Lawful Hemp Protection Act (H.R. 9830) introduced in July 2026. Most recently, on August 10, 2026, Representatives Beth Van Duyne (R-TX) and Greg Landsman (D-OH) introduced the bipartisan Beverage Regulatory Parity Act, which would establish an alcohol-style regulatory framework for hemp-derived beverages, a development directly relevant to the Company's Oasis brand.
Deliberate investments and one-time costs affected the bottom line. Results reflected more than $100,000 in legal and due-diligence expenses on additional M&A opportunities, continued investment in product development and clinical/regulatory initiatives, including our recent self-GRAS at 200mg per day, and incremental supply-chain and state-level compliance costs, including higher inventory reserves. The Company also identified additional supply-chain savings and, beginning in the fourth quarter of fiscal 2026, implemented cost-reduction initiatives targeting $100,000 to $150,000 in monthly savings (approximately $1.2 million to $1.8 million annualized) expected to improve future financial results and position the Company for a post-regulation market.

Financial Highlights from the Third Quarter of Fiscal Year 2026

Net sales totaled $5.6 million in the third quarter of fiscal 2026, an increase of 20% compared to $4.6 million in the third quarter of fiscal 2025. For the nine months ended June 30, 2026, net sales were $16.2 million, an increase of 12% compared to $14.5 million in the prior-year period.
Direct-to-consumer (e-commerce) net sales were $3.9 million, or 70% of total net sales, an increase of approximately 9% from the third quarter of fiscal 2025. The increase was attributed to addition of Bluebird, with some offsets related to increased state level restrictions.
Wholesale net sales were $1.7 million, or 30% of total net sales, an increase of 61% from the third quarter of fiscal 2025, reflecting continued progress with the Oasis brand and core cbdMD initiatives.
Gross profit as a percentage of net sales was 54.7% in the third quarter of fiscal 2026, compared to 61.5% in the prior-year quarter, primarily reflecting a shift in sales mix toward wholesale, incremental warehouse and repacking costs related to changing state-level requirements, and an increase in inventory reserves in anticipation of pending regulatory changes.
Loss from operations was approximately $1.13 million in the third quarter of fiscal 2026, compared to a loss of approximately $0.90 million in the prior-year period, reflecting the one-time and investment items described above.
Non-GAAP Adjusted EBITDA loss was approximately $508,000 in the third quarter of fiscal 2026, an improvement from an Adjusted EBITDA loss of approximately $624,000 in the third quarter of fiscal 2025.
Net loss attributable to common shareholders for the third quarter of fiscal 2026 was approximately $1.2 million, or $0.11 per share, compared to a net loss of approximately $1.2 million, or $0.21 per share, in the prior-year quarter. For the nine months ended June 30, 2026, net loss attributable to common shareholders improved to approximately $2.4 million, or $0.24 per share, from approximately $3.7 million, or $1.56 per share, in the prior-year period.
At June 30, 2026, the Company had working capital of approximately $4.7 million and cash on hand of approximately $2.1 million, compared to working capital of approximately $3.4 million and cash on hand of approximately $2.3 million at September 30, 2025.

Conference Call Details

The Company will host a conference call at 4:20 pm Eastern Time, on August 13, 2026, to discuss its third quarter fiscal 2026 financial results and business progress.

USA/Canada Dial-in: 888-880-3330
Webcast / Webcast Replay link: https://app.webinar.net/PGD52PJopeq

About cbdMD, Inc.

cbdMD, Inc. (NYSE American: YCBD) is one of the leading and most highly trusted and recognized cannabidiol (CBD) brands, with a comprehensive line of U.S.-produced THC-free1 CBD products and an array of Farm Bill-compliant Delta 9 products. The Company owns and operates the cbdMD, Paw CBD, and Bluebird Botanicals CBD brands, the Oasis line of hemp-derived THC beverages, the Kavari line of Kava products, and the ATRx Labs functional-mushroom brand. To learn more about cbdMD and its other brands, please visit www.cbdmd.com, www.pawcbd.com, www.ATRxLabs.com, www.bluebirdbotanicals.com, or www.herbaloasis.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD's products.

1 THC-free is defined as below the level of detection using validated scientific analytical methods.

Forward-Looking Statements

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as "should," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," "proposes," "will," "could," "would," "potential," "continue," "seek," and similar expressions. These forward-looking statements include, but are not limited to, statements regarding: our ability to continue as a going concern; our expectations regarding revenue growth and the performance of our core business and Oasis brand; our ability to drive improved operating results and move closer to sustainable profitability; the expected benefits, synergies, and integration of the Bluebird Botanicals acquisition and our pursuit of additional acquisitions; the anticipated benefits of our cost-reduction and supply-chain initiatives; our expectations regarding federal and state regulatory developments, including proposed legislation and the effective date of Section 781 of the Act, and their impact on our business; and our liquidity and working capital position. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. Factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to: our ability to continue as a going concern and maintain adequate liquidity; our ability to increase revenues and achieve profitability; our ability to successfully integrate Bluebird Botanicals and realize anticipated synergies and benefits; changes in consumer demand for CBD and hemp-derived products; our ability to maintain compliance with NYSE American continued listing requirements; changes in federal and state laws and regulations governing hemp, CBD, and cannabis products, including the potential impact of Section 781 of the Act and related legislation; our ability to compete effectively in a highly competitive market; our ability to maintain and expand our distribution channels; our ability to develop and successfully launch new products; disruptions in our supply chain or manufacturing operations; our ability to protect our intellectual property; cybersecurity risks and data privacy concerns; our ability to attract and retain key personnel; general economic conditions and their impact on consumer spending; and other risks and uncertainties described under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, and our other filings with the Securities and Exchange Commission (the "SEC"). All forward-looking statements in this press release are made as of the date hereof, based on information available to us as of the date hereof, and we assume no obligation to update any forward-looking statements except as required by applicable law. The information which appears on our websites and our social media platforms is not part of this press release.

cbdMD, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

JUNE 30, 2026 AND SEPTEMBER 30, 2025

(unaudited)

June 30,

September
30,

2026

2025

Assets

Cash and cash equivalents

$         21,18,339

$       22,61,242

Accounts receivable, net

17,52,661

10,40,887

Inventory, net

32,78,436

27,32,127

Inventory prepaid

1,86,763

2,14,795

Prepaid sponsorship

21,161

25,231

Prepaid expenses and other current assets

3,39,162

2,77,147

Total current assets

76,96,522

65,51,429

Other assets:

Property and equipment, net

3,34,840

2,77,377

Operating lease assets

21,83,117

7,03,934

Deposits for facilities

62,708

62,708

Intangible assets, net

19,78,646

21,24,502

Goodwill

1,90,000

-

Investment in other securities, noncurrent

7,00,000

7,00,000

Total other assets

54,49,311

38,68,521

Total assets

$      1,31,45,833

$    1,04,19,950

CONSOLIDATED BALANCE SHEETS

JUNE 30, 2026 AND SEPTEMBER 30, 2025

(continued)

June 30,

September 30,

2026

2025

Liabilities and shareholders' equity

Current liabilities:

Accounts payable

$         14,92,250

$       11,73,642

Accrued expenses

5,87,767

7,35,672

Operating leases - current portion

3,50,949

7,78,240

Note payable

7,321

-

Total current liabilities

30,79,569

31,93,843

Long term liabilities:

Operating leases - long term portion

15,83,994

-

Total long term liabilities:

15,83,994

-

Total liabilities:

46,63,563

31,93,843

Commitments and Contingencies

cbdMD, Inc. shareholders' equity:

Preferred stock, authorized 50,000,000 shares, $0.001

par value, 1,591,210 and 1,700,000 shares issued and outstanding,
respectively

1,591

1,700

Common stock, authorized 150,000,000 shares, $0.001

par value, 11,118,820 and 8,917,054  shares issued and outstanding,
respectively

11,119

8,917

Additional paid in capital

19,00,34,330

18,66,50,640

Accumulated deficit

(18,18,34,770)

(17,94,35,150)

Total cbdMD, Inc. shareholders' equity

82,12,270

72,26,107

Total liabilities and shareholders' equity

$      1,28,75,833

$    1,04,19,950

cbdMD, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2026 AND 2025

(unaudited)

Three months ended June 30,

Nine months ended June 30,

2026

2025

2026

2025

Gross Sales

$         55,53,738

$       46,06,796

$ 1,62,10,701

$ 1,44,69,698

Total Net Sales

$         55,53,738

$       46,06,796

$ 1,62,10,701

$ 1,44,69,698

Cost of sales

$         25,16,204

$       17,75,709

$    69,14,955

$    52,78,638

Gross Profit

$         30,37,534

$       28,31,087

$    92,95,746

$    91,91,060

Operating expenses

$         41,68,011

$       37,35,773

$ 1,15,13,299

$ 1,06,67,834

Loss from operations

$        (11,30,477)

$        (9,04,686)

$   (22,17,553)

$   (14,76,774)

Decrease (increase) in fair value of convertible debt

$                        -

$                      -

$                   -

$         87,380

Interest expense (income)

$                3,275

$              9,414

$           9,238

$         28,460

Loss before provision for income taxes

$        (11,27,202)

$        (8,95,272)

$   (22,08,315)

$   (13,60,934)

Net (loss) income

$        (11,27,202)

$       (8,95,272)

$   (22,08,315)

$   (13,60,934)

Preferred dividends

$              71,031

$         3,33,500

$      1,91,307

$    23,34,501

Net Loss attributable to cbdMD, Inc. common
shareholders

$        (11,98,233)

$     (12,28,772)

$   (23,99,622)

$   (36,95,435)

Net Loss per share:

Basic and diluted earnings per share

$                 (0.11)

$              (0.21)

$          (0.24)

$          (1.56)

Weighted average number of shares Basic and Diluted:

1,06,16,617

57,83,354

1,00,16,121

23,76,157

cbdMD, INC.

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE NINE MONTHS ENDED JUNE, 2026 AND 2025

(unaudited)

June 30,

June 30,

2026

2025

Cash flows from operating activities:

Net Loss

$     (22,08,315)

$        (13,60,934)

Adjustments to reconcile net loss to net

cash used by operating activities:

Restricted stock expense

$        3,62,109

$                3,693

Issuance of stock for services

$                     -

$              82,250

Intangibles amortization

$        6,12,751

$           5,73,801

Depreciation

$        1,43,210

$           2,90,275

Decrease in fair value of convertible debt

$                     -

$             (87,380)

Amortization of operating lease asset

$        5,24,525

$           4,99,309

Changes in operating assets and liabilities:

Accounts receivable

$       (6,90,727)

$              17,351

Inventory

$       (2,83,110)

$          (4,33,495)

Prepaid inventory

$           28,032

$          (2,21,034)

Prepaid expenses and other current assets

$           49,023

$              37,017

Accounts payable and accrued expenses

$           77,762

$          (1,94,632)

Operating lease liability

$       (5,77,005)

$          (4,23,855)

Deferred revenue / customer deposits

$          (15,377)

$                6,008

Cash flows from operating activities

$     (19,77,122)

$        (12,11,626)

Cash flows from investing activities:

Purchase of property and equipment

$       (1,88,615)

$          (1,81,368)

Purchase of Bluebird

$           56,427

$                        -

Cash flows from investing activities

$       (1,32,188)

$          (1,81,368)

Cash flows from financing activities:

Proceeds from ELOC draw

$           61,990

Proceeds from issuance of preferred stock

$      20,24,693

Preferred dividends distribution

$       (1,20,276)

$                        -

Cash flows from financing activities

$      19,66,407

$                        -

Net increase (decrease) in cash

$       (1,42,903)

$        (13,92,994)

Cash and cash equivalents, beginning of period

$      22,61,242

$         24,52,553

Cash and cash equivalents, end of period

$      21,18,339

$         10,59,559

Supplemental Disclosures of Cash Flow Information:

2026

2025

Cash Payments for:

Interest expense

$              19,046

Non-cash financing/investing activities:

Issuance of shares for conversion of debt and accrued interest

$                     -

$         10,79,639

Change in lease asset related to extinguishment of HQ lease and new warehouse lease

$                     -

$        (17,23,544)

ROU Assets obtained in exchange for lease liabilities

$      20,03,708

$                        -

All stock purchase of Bluebird

$        9,36,992

$                        -

Conversion of accrued preferred dividends to preferred stock

$                     -

$         66,72,652

Preferred dividends accrued but not paid

$           71,031

$         23,34,501

Non-GAAP Financial Measures

This press release includes a financial measure, Adjusted EBITDA, that excludes the impact of certain items and therefore has not been calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). cbdMD, Inc. defines Adjusted EBITDA as GAAP loss from operations adjusted to (i) depreciation and amortization, (ii) stock-based compensation expense, (iii) inventory reserve, (iii) regulatory and legal matters, and (iv) mergers and acquisitions and financing transaction expenses for the periods presented. cbdMD, Inc. has included Adjusted EBITDA because management uses this measure to assess operating performance and to highlight trends in the business that may not otherwise be apparent when relying on GAAP measures. This non-GAAP financial measure should not be considered as an alternative to, or more meaningful than, loss from operations as an indicator of operating performance and, as presented, may not be comparable to similarly titled measures reported by other companies. A reconciliation to the most directly comparable GAAP measure is provided below.

Reconciliation of GAAP Loss from Operations to Non-GAAP Adjusted EBITDA (Unaudited)

cbdMD, Inc.

NON GAAP ADJUSTED EBITDA

FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2026 AND 2025

(unaudited)

Three months ended June 30,

Nine months ended June 30,

2026

2025

2026

2025

GAAP (loss) from operations

$     (11,30,477)

$          (9,04,686)

$     (22,17,553)

$   (5,72,088)

Adjustments:

Depreciation and Amortization (1)

$         2,58,969

$           2,80,172

$         7,55,962

$    5,83,903

Employee and director stock compensation (2)

$            65,159

$                   825

$         3,66,963

$         5,016

Inventory Reserve (3)

$         1,20,000

$         1,20,000

Regulatory and Legal Mattters (4)

$            53,000

$            53,000

Mergers and Acquisitions and financing transaction expense (5)

$         1,26,000

$                        -

$         1,57,671

$                 -

Non-GAAP adjusted EBITDA

$        (5,07,349)

$          (6,23,689)

$       (7,63,957)

$       16,831

(1) Represents depreciation of property, plant and equipment and amortization of the Company's intangible assets.

(2) Represents non-cash expense related to options, warrants, restricted stock expenses that have been amortized during the period.

(3) Represents additional inventory reserve in preparation for pending regulatory changes.

(4) Represents regulatory costs associated with pending legislation.

(5) Represents costs associated with the Bluebird acquisition, preferred stock offerings and review of additional potential acquisition opportunities.

Contacts

Investors:
cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer
[email protected]
(704) 445-3064

SOURCE cbdMD, Inc.

Senate continuing resolution text released August 2 would delay the pending November federal hemp restrictions.

, /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), a leading and trusted manufacturer and distributor of hemp-derived cannabidiol (CBD) products through its cbdMD, Bluebird Botanicals, Herbal Oasis, and Paw CBD brands, today welcomed newly released Senate spending legislation that would preserve access to full-spectrum CBD and other naturally derived hemp products.

On August 2, leaders of the Senate Appropriations Committee released the text of a continuing resolution to fund federal agencies through December 11. Notably, the bill includes provisions that would delay the pending federal restrictions on most hemp products, currently scheduled to take effect November 12, until December 11. The U.S. Hemp Roundtable characterized the development as potentially "a landmark victory for the hemp industry," calling it the biggest win since the 2018 Farm Bill legalized hemp.

The measure would temporarily preserve the current federal framework for naturally derived hemp products during the extension. It includes a carve-out under which certain synthetic cannabinoids "not capable of being naturally produced by a Cannabis sativa L. plant" would still be affected on the original November 12 timeline. cbdMD's current assessment is that its core portfolio built on naturally derived, full-spectrum CBD and other hemp-derived formulations falls within the category the Senate text is intended to protect.

The Company notes that the Senate text is not yet law. The House of Representatives previously passed a version of the continuing resolution without these hemp provisions, so the language would need to be retained through final House and Senate action and signed by the President before taking effect. The Company will continue to monitor the process closely.

"This is a bridge, not the finish line.  It is an encouraging step for our industry and the consumers we serve," said T. Ronan Kennedy, Chief Executive Officer of cbdMD. "For the first time, protection for naturally derived hemp products is written into the base text of a must-pass spending bill, rather than left to an amendment fighting for a vote. If enacted, it would preserve access to the full-spectrum CBD products that millions of Americans rely on and give our industry a seat at the table as Congress works toward permanent, sensible rules. cbdMD has spent nearly a decade building brands around the standards responsible regulation should require, including third-party testing, transparent labeling, and age verification, and we intend to be a constructive voice as this process moves forward."

The Company views the proposed extension not as a new deadline, but as an opening. If enacted, the short-term extension would keep the hemp issue open through December 11, giving Congress an opportunity to include a more durable regulatory framework in a Farm Bill, omnibus appropriations package, or year-end extenders package. This progress follows months of engagement by businesses, farmers, consumers, and advocates, as well as public support from the White House for continued access to full-spectrum CBD.

cbdMD's products are supported by third-party laboratory testing and quality-assurance protocols, and the Company supports federal and state efforts to establish uniform standards for the manufacture, testing, labeling, and responsible sale of hemp-derived wellness products.

About cbdMD, Inc.

cbdMD, Inc. (NYSE American: YCBD) is a Charlotte, North Carolina company that manufactures and distributes hemp-derived cannabidiol products, including its flagship cbdMD, Bluebird Botanicals, Herbal Oasis, and Paw CBD brands and its functional-wellness brand ATRx Labs. cbdMD's mission is to enhance its customers' overall sense of well-being through premium, thoughtfully formulated products backed by third-party testing. For more information, visit www.cbdmd.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Words such as "believe," "expect," "would," "if enacted," "positioned," "will," and similar expressions are intended to identify forward-looking statements. These statements are based on management's current expectations and are subject to risks and uncertainties, including the uncertain outcome and timing of the Senate continuing resolution and related federal and state legislation and regulation affecting hemp-derived cannabinoids; the possibility that the hemp provisions are removed or altered before enactment; the potential impact of the hemp definition currently scheduled to take effect on November 12, 2026, and any delay of that date; the scope of any synthetic-cannabinoid carve-out; the Company's ability to comply with and adapt to evolving legal requirements; market, competitive, and economic conditions; and other risks described in the Company's filings with the U.S. Securities and Exchange Commission. Actual results may differ materially from those expressed or implied. The Company undertakes no obligation to update any forward-looking statement except as required by law. Nothing in this release constitutes legal, regulatory, or investment advice, and no assurance can be given that any proposed legislation will be enacted or that any particular regulatory outcome will occur.

Contacts
cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer
[email protected]
(704) 445-3064

SOURCE cbdMD, Inc.

Hemp-derived THC beverages, including the new zero-proof Mixer, roll out to liquor retailers statewide

, /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD) today announced that its Oasis line of hemp-derived beverages is now available in South Carolina through a new distribution agreement with Morales Beverage Group, South Carolina, a leading beverage statewide alcohol distributor. The agreement places Oasis products on liquor store shelves across the state, giving South Carolina consumers direct access to the brand at established retail destinations.

The rollout includes the the full Oasis portfolio, featuring the brand's newest release, the zero proof spirit style Mixer, a spirit-style hemp-derived beverage designed for consumers looking for a versatile option for cocktails and mixed drinks. Oasis products are now stocked at retailers throughout South Carolina, including Frugal MacDoogal, one of the Carolinas' best-known beverage destinations.

"South Carolina is an important market for Oasis, and Mexcor is the right partner to help us reach consumers where they already shop for spirits, wine, and beer," said Ronan Kennedy, CEO of cbdMD. "Getting Oasis, and especially Mixer, onto liquor store shelves alongside traditional beverage alcohol is exactly the kind of placement that introduces the brand to a broader audience."

"Its always a challenge as a distributor to make decisions on what new products to bring to the market. The team at Herbal Oasis made it very easy. A well-established company from the Carolinas, proven sales in other markets, and quality and innovation that is out pacing the industry. It was an easy yes! I'm very excited to be representing this brand in the state of South Carolina", said Adam Howard, General Manager of MGB South Carolina.

Placing Oasis within the established liquor retail channel reflects the brand's strategy of meeting adult consumers in familiar shopping environments and positioning hemp-derived beverages as an approachable option within the broader beverage category. Mexcor's distribution network and retail relationships across South Carolina provide a foundation for expanding availability over time.

Oasis products are crafted to quality and testing standards consistent with cbdMD's broader commitment to transparency and responsible product development. All Oasis products are intended for adults of legal purchasing age.

About cbdMD, Inc.
cbdMD, Inc. (NYSE American: YCBD) is a consumer wellness company building a multi-brand platform across hemp-derived wellness, beverages, pet wellness, botanical wellness, and related consumer categories. Its portfolio includes cbdMD, Paw CBD, Oasis, and Bluebird Botanicals. For more information, visit www.cbdmd.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding product distribution, retail availability, market expansion, consumer demand, and the Company's beverage strategy. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including risks related to distribution and retail relationships, evolving federal and state regulation of hemp-derived products, the Company's ability to maintain regulatory compliance, and other risks described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contacts

cbdMD, Inc.

Ronan Kennedy

Chief Executive Officer and Chief Financial Officer

[email protected]

(704) 445-3064

SOURCE cbdMD, Inc.

Years of peer-reviewed safety research position cbdMD's broad spectrum CBD for a new era of evidence-based, clinically supported wellness.

, /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's most recognized and trusted hemp-derived wellness companies, today announced the completion of a self-affirmed Generally Recognized as Safe (GRAS) determination supporting the safe consumption of up to 200 mg per day of cannabidiol (CBD), as delivered in the Company's proprietary broad spectrum hemp extract, in healthy adults, addressing one of the most common questions in the category of how much CBD is safe to consume per day.

The self-affirmed GRAS determination represents the culmination of years of scientific investment by cbdMD to establish a comprehensive body of evidence supporting the safety of its broad spectrum CBD products. Over the past several years, the Company has worked to develop a substantial dossier of safety data, including studies conducted in rodents, healthy human volunteers, and canines, designed to characterize the safety profile of its broad spectrum CBD formulations. This research has been published in the peer-reviewed scientific literature, spanning toxicology, genotoxicity, human tolerability, and companion-animal studies, a depth of published evidence that distinguishes cbdMD within the hemp-derived CBD category.

This extensive body of evidence was assembled through a rigorous scientific program that evaluated multiple aspects of safety across relevant preclinical and clinical models. The resulting safety dossier forms the foundation of the Company's self-affirmed GRAS conclusion, which supports the intended use of cbdMD's broad spectrum CBD products at a daily intake of up to 200 mg for healthy adults. The determination was made by an independent panel of expert toxicologists following a review of the available scientific literature on the safety of cannabidiol.

"The completion of our self-affirmed GRAS determination for the CBD contained in our proprietary broad spectrum blend marks a significant scientific and regulatory milestone for cbdMD," said Ronan Kennedy, CEO of cbdMD. "We have invested for years in building a robust portfolio of safety data because we believe consumers, healthcare professionals, and industry stakeholders deserve products supported by high-quality science. This achievement reflects our longstanding commitment to product quality, transparency, and scientific rigor."

The determination lands at a pivotal moment for the category. In 2026, the Centers for Medicare & Medicaid Services (CMS) launched the Substance Access Beneficiary Engagement Incentive, a first-of-its-kind initiative under which participating care organizations may offer eligible patients physician-guided access to non-intoxicating, third-party-tested hemp-derived CBD, and the U.S. Food and Drug Administration signaled enforcement discretion for orally administered CBD products meeting dietary-supplement standards in that context. As policymakers move to bring evidence-based CBD into mainstream care, cbdMD's published safety science reflects the standards this new era demands.

The safety substantiation also supports cbdMD's ability to develop and position products across a range of formats and use occasions, from daily wellness to targeted active-lifestyle and recovery applications, and to serve both direct-to-consumer and healthcare-oriented channels. By establishing a science-backed daily intake ceiling, the determination gives clinicians, retail partners, and consumers a clear reference point for confident, consistent use across the Company's broad spectrum product line.

The Company believes this milestone further demonstrates its leadership in advancing science-based standards for hemp-derived wellness products and reinforces its commitment to supporting consumer confidence through rigorous research and responsible product development.

cbdMD's Published Safety Research

cbdMD's contributions to the peer-reviewed scientific literature on cannabinoid safety span several study types and species. They include subchronic oral toxicity and genotoxicity assessments of the Company's cannabis extract (Tallon et al., 2023, Regulatory Toxicology and Pharmacology); and Tallon et al., 2025, Pharmaceutical Biology); pharmacokinetic and tissue-accumulation research (Child & Tallon, 2022, Nutrients); a double-blind, randomized controlled trial of tolerability in healthy adults (Mastrofini et al., 2024, Journal of the International Society of Sports Nutrition); and a double-blind, placebo-controlled study in dogs (Talsma et al., 2024, Frontiers in Veterinary Science). These studies were sponsored by cbdMD, Inc. and were conducted in collaboration with independent research organizations, academic investigators, and accredited laboratories.

About cbdMD, Inc.

cbdMD, Inc. (NYSE American: YCBD) is a leading wellness company offering a comprehensive line of U.S.-produced, hemp-derived cannabinoid products, including CBD, CBG, CBN, and more. Its brands include cbdMD, one of the most trusted and recognized CBD brands in the United States; Bluebird Botanicals; Paw CBD, one of the most recognized CBD brands for pets; ATRx Labs functional mushroom supplements; and Oasis, a hemp-derived THC social beverage line. The Company is committed to quality, innovation, science, and transparency, with products distributed both online and through retail partners across the United States. To learn more, please visit www.cbdmd.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Words such as "expect," "will," "believe," "designed to," "anticipate," and similar expressions are intended to identify forward-looking statements, including statements regarding the product's attributes and regulatory compliance and CBD safety and efficacy determinations. Forward-looking statements are based on management's current expectations and assumptions and are subject to known and unknown risks and uncertainties, including evolving federal and state regulation of hemp-derived THC products, that could cause actual results to differ materially, including those described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement except as required by law.

Contacts
cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer
[email protected]
(704) 445-3064

SOURCE cbdMD, Inc.

As federal reclassification efforts advance and major U.S. exchanges open to compliant operators, cbdMD points to its position as an established, NYSE American–listed company in a maturing cannabinoid category

, /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's most recognized and trusted hemp-derived wellness companies, today welcomed the Administration's call urging Congress to ensure the fair treatment of hemp-derived products under federal law and requesting immediate action to revise federal hemp regulation to ensure fair treatment of hemp products under federal law.

In a letter to congressional leadership this week, the White House Office of Management and Budget identified hemp reform as a priority the Administration strongly supports. The request calls on Congress to ensure fair treatment of hemp-derived products by preserving access to appropriate full-spectrum CBD products, while preserving Congress's intent to restrict products that pose health risks. The Administration also urged Congress to adopt a responsible federal framework or, at minimum, extend the current implementation timeline so that lawmakers have time to get the policy right. The request builds on the President's earlier public statements urging lawmakers to protect access to the full-spectrum CBD products that millions of Americans rely on.

"We are encouraged to see the Administration advocating so clearly for responsible, science-backed hemp products that consumers depend on every day," said Ronan Kennedy, Chief Executive Officer of cbdMD. "cbdMD has always believed the future of this category is built on quality, transparency, and clear rules that distinguish responsible operators from bad actors. A federal framework that protects consumer access, promotes safety, and provides certainty for compliant companies is exactly what this industry and the people it serves deserve. We commend the policymakers who are working toward that outcome."

Separately, broader federal cannabis policy developments continue to draw investment, research, and institutional attention to the cannabinoid category. Notably, major U.S. exchanges have begun permitting the listing of the plan-touching operators that comply with federal, state and local medical cannabis framework. Although cannabis reclassification is distinct from the federal treatment of hemp-derived products, recent exchange-listing developments for compliant cannabis operators reflect a market that is moving toward greater legitimacy, transparency, and regulatory maturity. As an established hemp-derived wellness company with recognized brands, national distribution, and a listing on a national securities exchange, cbdMD believes it is well-positioned as the cannabinoid category moves toward greater maturity, transparency, and regulatory clarity.

"We believe cbdMD is purpose built for this next phase of the market," Kennedy added. "Our focus remains on serving our customers with trusted, efficacious products, supporting responsible regulation, and building long-term value for our shareholders as the category continues to evolve. Along the way, we will continue to evaluate the opportunities this evolving environment may present."

About cbdMD, Inc.

cbdMD, Inc. (NYSE American: YCBD) is a leading wellness company headquartered in Charlotte, North Carolina, with a portfolio of trusted hemp-derived and wellness brands, including cbdMD, Bluebird Botanicals, Paw CBD, ATRx Labs, and the Oasis line of hemp-derived THC beverages. The Company is committed to quality, science, and transparency across its product lines. For more information, visit cbdmd.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding potential changes to the federal regulatory framework for hemp-derived products; the timing or outcome of legislative, administrative, or agency action; the evolution of U.S. capital markets and securities exchange listing practices for the cannabinoid category; and the Company's competitive position and potential opportunities. These statements are based on management's current expectations and are subject to known and unknown risks and uncertainties.

Such risks include, without limitation: that Congress or the Administration may not act, may act on a different timeline, or may adopt adverse regulation or regulation different from what is currently proposed; the potential impact of the statutory changes to the federal definition of hemp scheduled to take effect November 12, 2026; the fact that the ongoing federal cannabis reclassification proceedings concern marijuana, are separate from and do not directly govern the regulation of hemp-derived products, and may not conclude on the timeline or with the outcome the Company anticipates; that securities exchange practices regarding the listing of cannabis-related companies may change or may not develop as expected; and other risks described in the Company's filings with the Securities and Exchange Commission. Actual results may differ materially from those expressed or implied. The Company undertakes no obligation to update any forward-looking statement except as required by law.

Contacts

cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer
[email protected]
(704) 445-3064

SOURCE cbdMD, Inc.

Company brings one of the only combined clinical and toxicological safety dataset in the hemp-derived CBD category into a new provider channel as CMS activates cannabinoid access within value-based care models

, /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), a leader in science-driven cannabinoid products, today announced the launch of its clinical healthcare channel, positioning the Company to support physicians, health systems, and value-based care organizations as federal policy establishes structured pathways for hemp-derived cannabinoid products within Medicare programs.

On March 20, 2026, the Centers for Medicare & Medicaid Services (CMS) published operational guidance activating the Substance Access Beneficiary Engagement Incentive (BEI), an existing incentive mechanism within CMS Innovation Center models, to include eligible hemp-derived cannabinoid products for the first time. Effective April 1, 2026, participating accountable care organizations and oncology practices in select models, including the Enhancing Oncology Model (EOM) and ACO REACH, may furnish eligible hemp-derived products to Medicare patients as part of physician-supervised care. The upcoming LEAD Model also incorporates the BEI framework when it is expected to launch on January 1, 2027. Together these models encompass thousands of physicians and millions of aligned Medicare beneficiaries.

The BEI remains a limited, model-specific initiative, not a broad access or reimbursement program, and participating organizations independently determine supplier relationships.

"Healthcare is where this category has always needed to go," said Ronan Kennedy, Chief Executive Officer of cbdMD. "This is the inflection point. CMS has established a structured, physician-supervised framework for hemp-derived cannabinoids within Medicare, and the bar to participate credibly is high requiring clinical data, institutional-grade documentation and healthcare supply infrastructure. cbdMD has spent years preparing for such framework."

cbdMD is entering the clinical channel with a scientific and regulatory platform the Company believes is unmatched in the hemp-derived CBD category. To the Company's knowledge, no other hemp-derived CBD manufacturer has published both OECD-standard preclinical toxicology data and human randomized controlled trial data for its commercial product lines. That foundation includes:

Published preclinical safety data: A 90-day subchronic oral toxicity study conducted to OECD 408 guidelines, the international standard used in pharmaceutical safety assessment, demonstrating safety margins significantly above expected human dosing levels
  Human clinical evidence: Data from an IRB-approved, randomized, double-blind, placebo-controlled trial confirming safety and tolerability in human subjects
  GRAS regulatory status: Self-affirmed Generally Recognized As Safe (GRAS) dossiers supporting key product categories,the same safety standard applied to conventional food and supplement ingredients reviewed by the FDA
  Healthcare-grade supply chain: Batch-level traceability, certificate of analysis documentation, and quality systems designed for institutional procurement and compliance review In parallel, cbdMD is developing a dedicated provider-focused product line with formulations, documentation, and labeling structured specifically for clinical environments, along with infrastructure to support multi-site health systems and value-based care organizations.

"We recognize physicians and health systems evaluating this category will not accept consumer-grade marketing claims or products without published safety data," said Sibyl Swift, Ph.D., member of board of directors and scientific consultant of cbdMD. "They require OECD-standard toxicology, human clinical data, drug interaction transparency, and documentation that can withstand institutional review. That evidence base does not exist broadly in this category, cbdMD has built it. That is where we are focused."

The Company is actively engaging accountable care organizations, oncology practices, and health systems as they evaluate implementation under the BEI and broader clinical integration of cannabinoid products. cbdMD believes that provider adoption in this channel will be driven by demonstrated safety, data transparency, and operational reliability; standards the Company has been building toward for years. The company is also pursuing research partnerships with healthcare organizations and academic institutions to generate real-world outcomes data on hemp CBD in physician-supervised Medicare settings.

cbdMD is also monitoring the FDA's recent submission of updated regulatory considerations for hemp-derived CBD products to the White House Office of Information and Regulatory Affairs, which the Company views as part of a continued shift toward a more clearly defined, evidence-based federal framework for cannabinoid products.

Healthcare organizations interested in cbdMD's clinical channel, product documentation, or supply capabilities are encouraged to contact the Company directly.

Clinical channel inquiries: [email protected]

About the CMS Substance Access BEI The Substance Access Beneficiary Engagement Incentive, effective April 1, 2026, allows participating organizations in CMS Innovation Center models — including ACO REACH, the Enhancing Oncology Model, and the upcoming LEAD Model — to furnish eligible hemp-derived CBD products to Medicare patients through physician-supervised consultations. CMS does not reimburse product costs, does not designate preferred or approved suppliers, and does not cover products as a Medicare benefit. Participating organizations make independent clinical and procurement decisions.

About cbdMD, Inc. cbdMD, Inc. (NYSE American: YCBD) is a science-driven cannabinoid company offering a portfolio of hemp-derived CBD products under the cbdMD, Bluebird Botanicals, Paw CBD, and Herbal Oasis brands. The Company has invested in clinical research, toxicological safety studies, and GRAS regulatory dossiers, establishing what it believes is the most comprehensive published safety and clinical dataset in the U.S. hemp-derived CBD category. cbdMD products are available direct-to-consumer at cbdmd.com, through thousands of retail locations, and through the Company's newly launched clinical healthcare channel. Learn more at cbdmd.com.

Forward Looking Statements

This press release contains statements, estimates, forecasts, and projections regarding future performance and events that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Those statements include statements regarding expectations from evolving federal regulation, the development of cbdMD's clinical healthcare channel and platform, Medicare requirements, market acceptance of CBD clinical healthcare products and the ability of cbdMD to furnish eligible hemp-derived CBD products to Medicare patients. These statements may be identified by the use of words like "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "will," "should," and "seek," and similar expressions and include any financial projections or estimates or pro forma financial information set forth herein. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those projected in the forward-looking statements. Important factors and risks that could cause actual results to differ materially from our expectations include, but are not limited to, participating organizations in CMS Innovation Center models acceptance of eligible hemp-derived CBD products to be furnished to Medicare patients; customer, professional healthcare provider and Medicare acceptance of our product offerings; and costs and expenses to develop a clinical healthcare channel and products, as well as those risks detailed in our filings with the SEC, including our most recent Form 10-K and other filings with the SEC.

Contact Information: 

Investors:
cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer
[email protected]
(704) 445-3064

SOURCE cbdMD, Inc.

CHARLOTTE, N.C. , May 14, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading and most trusted CBD companies and operator of the cbdMD, Bluebird Botanicals, and Paw CBD brands, along with its THC beverage brand Oasis, today announced financial results for the second quarter of fiscal year 2026, ended March 31, 2026.